- Artios to receive $20 million up-front payment in addition to near term research funding to support the collaboration.
- Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
LONDON, 07 April 2021: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhance Novartis’ Radioligand Therapies (RLT).
